Vascular dysfunction in diabetes: The endothelial progenitor cells as new therapeutic strategy

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

332

HTML

4300

Tables (1-1)

207

Sum=4839

Jun 15, 2011 (publication date) through Nov 24, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Diabetes. Jun 15, 2011; 2(6): 92-97
Published online Jun 15, 2011. doi: 10.4239/wjd.v2.i6.92

Table 1 Summarizes the potential therapeutic targets to increase EPC number or function

Signaling pathways	Specific drugs
Angiotensin-Convering-Enzyme (ACE)	Ramipril; Enalapril
Angiotensin II	Valsartan
PI3-K/Akt/eNOS/NO	Statins
Reactive oxygen species (ROS)	SOD
CXCR4	AMD3100

Citation: Georgescu A. Vascular dysfunction in diabetes: The endothelial progenitor cells as new therapeutic strategy. World J Diabetes 2011; 2(6): 92-97
URL: https://www.wjgnet.com/1948-9358/full/v2/i6/92.htm
DOI: https://dx.doi.org/10.4239/wjd.v2.i6.92